Navigation Links
Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia
Date:6/14/2010

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL).  Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab. As of April 2010, six of nine evaluable, MRD responding, non-transplanted patients were in hematologic remission, ranging up to 23 months.  Historical experience suggests that the majority of patients with MRD following front-line chemotherapy who do not receive a transplant will relapse within one year.  Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

Dr. Max Topp, Department of Internal Medicine II, University of Wuerzburg presented the study findings on June 12, 2010 in an oral presentation (abstract # 0598) at the 15th Annual Congress of the European Hematology Association (EHA) in Barcelona, Spain.

"Adult acute lymphoblastic leukemia is a difficult to treat disease that has seen no meaningful improvement in decades," said Dr. Topp.  "These data clearly demonstrate that blinatumomab has the potential to fundamentally change the outcome for patients with ALL."

Phase 2 Study Design

This multi-center Phase 2 study evaluated the efficacy and safety of blinatumomab in ad
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
2. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
4. Newly Updated Pharmacy State Law Compendium Available
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
6. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
7. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
8. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
9. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
10. ORTHO EVRA(R) Prescribing Information Updated
11. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013  Millennium HealthCare Inc. (OTC ... into an exclusive 25-year Supply and Distribution agreement ... Corporation ("EWC") for its Distance Monitored Physical Therapy ... physical therapy program is a critical element in ... said Chris Amandola , president, Millennium HealthCare ...
(Date:6/18/2013)... , June 18, 2013  Specialty ... significant breakthrough in Parylene coating technologies: SCS ... the benefits of Parylene with antimicrobial properties ... devices and components. (Logo: ... infections (HAIs) increase and continue to pose ...
(Date:6/18/2013)... MPR is excited to unveil a new logo and ... of an ongoing effort to freshen the look and feel ... years. (Photo: http://photos.prnewswire.com/prnh/20130618/NY33937 ) ... has expanded upon its foundation as a concise drug information ... array of clinical and practice management tools including a cloud-based ...
Breaking Medicine Technology:Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 2Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions 3Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2MPR Sports a Bold New Look 2
... The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine ... as its July 2010 "Stock to Study" and Gilead ... for investors, informational and educational use. , ... "The committee chose Teva Pharmaceutical Industries because of the tremendous ...
... EAST BRUNSWICK, N.J. , April 30 Savient Pharmaceuticals, Inc. (Nasdaq: ... the first quarter 2010 following the close of the market on Wednesday ... , ... Financial Officer, will host an investment community conference call beginning at 10:00 ...
Cached Medicine Technology:BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 2BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 3Savient Pharmaceuticals To Hold First Quarter 2010 Results 2
(Date:6/18/2013)... June 18, 2013 Today, Zane Benefits, ... Reimbursement Accounts . Zane Benefits, which provides comprehensive and ... the leader in defined contribution and ... Benefits’ website, employees of a company who sets up ... questions about how Health Reimbursement Accounts work. Educating employees ...
(Date:6/18/2013)... New York, NY (PRWEB) June 18, 2013 ... Sinai Medical Center to its “Best Doctors” list, up ... in New York City. The new issue also lists 52 ... network, which continues on a strategic growth trajectory. The “Best ... physicians, appears in the June 24 print issue and is ...
(Date:6/18/2013)... Local chemical signals released by fat cells in the ... exposure to unrelenting social stressors early in life, and ... University of Chicago report in the July 2013 issue ... Some forms of stress exposure may be associated with ... cancer. But the mechanisms linking the biology of social ...
(Date:6/18/2013)... June as Lesbian, Gay, Bisexual and Transgender ... civil rights, sexual minority youth are still ... heterosexual peers, according to the Suicide Prevention ... graduate student recently published recommendation to improve ... could help improve psychological functioning and reduce ...
(Date:6/18/2013)... 2013)-- An international team of investigators co-led by Weill ... evidence-based surgery and device research, similar to the kind ... , "Currently, there is no dynamic research framework to ... benefits to patients or may even be harmful," says ... College. , In the June 18 issue of ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Health Reimbursement Accounts 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 3Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 2Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 3Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 4Health News:Sexual minority youth need specialized treatment from therapists 2Health News:Tackling a framework for surgical innovation 2Health News:Tackling a framework for surgical innovation 3
... published in the Journal of Vascular Surgery reported that ... better// when accompanied by a suction device to remove ... kidneys. ,Researchers from the Wake Forest University ... that short, less invasive procedures restored enough blood flow ...
... now investigating Dr Wakefield over claims of serious professional misconduct//. ... Wakefield and subsequently published in The Lancet in 1998, had ... might exist a causal link between the combined measles, mumps ... ,Reports now indicate that the GMC is now charging ...
... The death of a 65-year-old woman at the ... Ms Hannah Comber died //from asphyxiation after she ... special chair.,The HSE said, it is fully co-operating ... into the incident at a continuing care facility ...
... have found that astemizole, which is used for treating ... for treating malaria//. ,According to a study conducted ... Public Health and the Johns Hopkins University School of ... Malaria Research Institute (MRI), determined that in a test ...
... the urology segment, pharma major Dr Reddys Laboratories Ltd ... release tablets of 10 mg dosage. ... indicated for treatment of enlargement of prostate gland in ... company release said., ,The product was launched nationwide, ...
... volunteers have found that external ‘condom’ catheter showed lesser ... ,An 80 per cent reduction in urinary ... was collected with condom type catheter, which proved a ... ,In fact, men whose urine was collected with an ...
Cached Medicine News:Health News:Blood Flow to Kidneys Better Restored by Less Invasive Procedures 2Health News:Antihistamine Could also be used as a Potential Antimalarial Drug 2Health News:External Catheters Linked with decreased UTI Risk in Men 2Health News:External Catheters Linked with decreased UTI Risk in Men 3Health News:External Catheters Linked with decreased UTI Risk in Men 4
... GORE SEAMGUARD® Bioabsorbable Staple Line ... procedures in which soft tissue transection ... is needed.,The GORE SEAMGUARD Bioabsorbable Staple ... easy-to-use material for reinforcement of staple ...
... for temporary wound support. Especially suitable ... stretchable support material is desired and ... required. Predictable absorption. Polyglactin 910 has ... and nonpyrogenic. ,VICRYL (polyglactin 910) knitted ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... Biosurgical Composite is designed for the repair ... PPM mesh that has two distinct sides. ... coated with a layer of sodium hyaluronate ... Adhesion Barrier). This coated side is bioresorbable, ...
Medicine Products: